See more : Franklin Covey Co. (FC) Income Statement Analysis – Financial Results
Complete financial analysis of Humanigen, Inc. (HGEN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Humanigen, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Energy Development Company Limited (ENERGYDEV.BO) Income Statement Analysis – Financial Results
- Dream Incubator Inc. (4310.T) Income Statement Analysis – Financial Results
- Milestone Scientific Inc. (MLSS) Income Statement Analysis – Financial Results
- Hamilton Thorne Ltd. (HTLZF) Income Statement Analysis – Financial Results
- Eni S.p.A. (ENI.BR) Income Statement Analysis – Financial Results
Humanigen, Inc. (HGEN)
About Humanigen, Inc.
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called 'cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is also being studied in conjunction with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and in eosinophilic asthma, and rheumatoid arthritis. In addition, the company focuses on studying lenzilumab for patients with chronic myelomonocytic leukemia exhibiting RAS pathway mutations. Its pipeline also includes two other Humaneered monoclonal antibodies, ifabotuzumab, which binds to EphA3, and HGEN005, which targets EMR1. Ifabotuzumab has been evaluated in a Phase 1 study of glioblastoma multiforme that showed tumor specific targeting of all known tumor sites with no normal tissue uptake. HGEN005 is being explored as a treatment for a range of eosinophilic diseases, including eosinophilic leukemia as an optimized naked antibody and as the backbone for a novel CAR-T construct. Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.51M | 3.60M | 312.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 44.00K | 6.10M | 20.26M | 17.71M | 589.00K |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 2.51M | 3.60M | 312.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 44.00K | 6.10M | 20.26M | 17.71M | 589.00K |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 55.21M | 213.12M | 72.71M | 2.62M | 2.22M | 11.17M | 10.45M | 16.72M | 26.57M | 32.64M | 24.52M | 18.51M | 18.89M | 22.86M |
| General & Administrative | 15.61M | 23.25M | 15.80M | 6.33M | 9.11M | 7.87M | 8.38M | 14.30M | 10.15M | 8.31M | 5.06M | 4.01M | 4.94M | 5.19M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 15.61M | 23.25M | 15.80M | 6.33M | 9.11M | 7.87M | 8.38M | 14.30M | 10.15M | 8.31M | 5.06M | 4.01M | 4.94M | 5.19M |
| Other Expenses | 0.00 | -1.61M | -1.00K | -1.00K | 324.00K | 431.00K | 125.00K | -213.00K | -154.00K | -39.00K | 113.00K | -8.00K | 915.00K | 348.00K |
| Operating Expenses | 70.82M | 236.37M | 88.51M | 8.94M | 11.33M | 19.03M | 18.83M | 31.02M | 36.72M | 40.95M | 29.58M | 22.52M | 23.84M | 28.05M |
| Cost & Expenses | 70.82M | 236.37M | 88.51M | 8.94M | 11.33M | 19.03M | 18.83M | 31.02M | 36.72M | 40.95M | 29.58M | 22.52M | 23.84M | 28.05M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 29.00K | 88.00K | 86.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 2.92M | 2.26M | 1.34M | 1.35M | 852.00K | 3.06M | 131.00K | 842.00K | 1.21M | 1.09M | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 492.00K | -1.61M | -1.00K | -1.00K | 19.00K | 48.00K | 102.00K | 197.00K | 310.00K | 298.00K | 304.00K | 595.00K | 843.00K | 844.00K |
| EBITDA | -67.81M | -234.39M | -88.20M | -8.95M | -10.99M | -18.55M | -18.60M | -31.00M | -36.47M | -40.56M | -23.18M | -1.67M | -5.28M | -26.62M |
| EBITDA Ratio | -2,697.37% | -6,519.75% | -28,268.91% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -92,190.91% | -380.09% | -8.25% | -29.81% | -4,519.35% |
| Operating Income | -68.30M | -232.77M | -88.20M | -8.94M | -11.33M | -19.03M | -18.83M | -34.35M | -36.72M | -40.91M | -23.48M | -2.27M | -6.12M | -27.46M |
| Operating Income Ratio | -2,716.95% | -6,474.88% | -28,268.59% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -92,975.00% | -385.08% | -11.19% | -34.57% | -4,662.65% |
| Total Other Income/Expenses | -2.43M | -3.88M | -1.34M | -1.35M | -673.00K | -2.96M | -8.19M | -1.03M | -1.28M | -1.04M | -27.00K | 35.00K | 1.02M | 639.00K |
| Income Before Tax | -70.73M | -236.65M | -89.54M | -10.29M | -12.00M | -21.99M | -27.02M | -35.38M | -38.00M | -41.95M | -23.51M | -2.23M | -5.10M | -26.82M |
| Income Before Tax Ratio | -2,813.44% | -6,582.73% | -28,697.12% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -95,336.36% | -385.52% | -11.02% | -28.79% | -4,554.16% |
| Income Tax Expense | -492.00K | 2.26M | 1.34M | 1.35M | 179.00K | 3.49M | 256.00K | 629.00K | 1.06M | 1.05M | 140.00K | -43.00K | -108.00K | -19.00K |
| Net Income | -70.24M | -238.91M | -90.87M | -11.64M | -12.00M | -21.99M | -27.02M | -35.38M | -38.00M | -41.95M | -23.51M | -2.23M | -5.10M | -26.81M |
| Net Income Ratio | -2,793.87% | -6,645.70% | -29,125.32% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -95,336.36% | -385.52% | -11.02% | -28.79% | -4,550.93% |
| EPS | -1.18 | -4.08 | -2.46 | -0.52 | -0.63 | -7.34 | -13.92 | -42.88 | -46.09 | -69.13 | -448.66 | -46.17 | -97.33 | -85.16 |
| EPS Diluted | -1.18 | -4.08 | -2.46 | -0.52 | -0.63 | -7.34 | -13.92 | -42.88 | -46.09 | -69.13 | -448.66 | -46.17 | -97.33 | -85.16 |
| Weighted Avg Shares Out | 59.49M | 58.53M | 36.96M | 22.36M | 18.95M | 3.00M | 1.94M | 825.00K | 824.48K | 606.76K | 52.40K | 48.34K | 52.40K | 314.77K |
| Weighted Avg Shares Out (Dil) | 59.49M | 58.53M | 36.96M | 22.36M | 18.95M | 3.00M | 1.94M | 825.00K | 824.48K | 606.76K | 52.40K | 48.34K | 52.40K | 314.77K |
HGEN FINAL DEADLINE: ROSEN, A TOP RANKED FIRM, Encourages Humanigen, Inc. Investors With Losses Exceeding $100K to Secure Counsel Before Important Tuesday Deadline in Securities Class Action - HGEN
HGEN SHAREHOLDER ALERT: Jakubowitz Law Reminds Humanigen Shareholders of a Lead Plaintiff Deadline of October 25, 2022
HUMANIGEN, INC. (HGEN) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Humanigen, Inc. (HGEN)
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Humanigen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 25, 2022 - (NASDAQ: HGEN)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment Humanigen, Inc. of Class Action Lawsuit and upcoming Deadline - HGEN
GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages Humanigen, Inc. Investors to Secure Counsel Before Important October 25 Deadline in Securities Class Action – HGEN
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Humanigen, Inc. Investors to Secure Counsel Before Important October 25 Deadline in Securities Class Action - HGEN
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Humanigen, Inc. Investors With Losses to Secure Counsel Before Important October 25 Deadline in Securities Class Action - HGEN
Humanigen Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 25, 2022 to Discuss Your Rights - HGEN
ROSEN, Leading Investor Counsel, Encourages Humanigen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HGEN
Source: https://incomestatements.info
Category: Stock Reports